Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab
- 1 December 2001
- journal article
- clinical trial
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 20 (12) , 1282-1290
- https://doi.org/10.1016/s1053-2498(01)00356-4
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- A comparison of daclizumab to ATGAM induction in simultaneous pancreas‐kidney transplant recipients on triple maintenance immunosuppressionClinical Transplantation, 2000
- THE SAFETY AND EFFICACY OF A TWO-DOSE DACLIZUMAB (ZENAPAX) INDUCTION THERAPY IN LIVER TRANSPLANT RECIPIENTS1Transplantation, 2000
- Immunosuppressant-Induced NephropathyDrug Safety, 1999
- ATG Induction Therapy and the Incidence of Bronchiolitis Obliterans After Lung Transplantation: Does It Make a Difference?Transplantation Proceedings, 1998
- ANTILYMPHOCYTE INDUCTION THERAPY IN CADAVER RENAL TRANSPLANTATIONTransplantation, 1997
- Delayed Development of Obliterative Bronchiolitis Syndrome With OKT3 After Unilateral Lung TransplantationChest, 1996
- Cytolytic Therapy for the Bronchiolitis Obliterans Syndrome Complicating Lung TransplantationChest, 1996
- Obliterative bronchiolitis after lung and heart-lung transplantationThe Annals of Thoracic Surgery, 1995
- Obliterative bronchiolitis after lung and heart-lung transplantationThe Journal of Thoracic and Cardiovascular Surgery, 1995
- Acute rejection of lung allografts with various immunosuppressive protocolsThe Annals of Thoracic Surgery, 1992